Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal cell carcinoma.

P A Godley1, M Taylor

  • 1University of North Carolina at Chapel Hill, Division of Hematology/Oncology, and the Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599-7305, USA.

Current Opinion in Oncology
|April 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hospitals lose appeal in 'outlier' pay case.

Modern healthcare·2001
Same author

How much will the whistleblowers get?

Modern healthcare·2001
Same author

N.Y. alliance may have to break up.

Modern healthcare·2001
Same author

Insurers pursue HCA on fraud charges.

Modern healthcare·2001
Same author

Judge orders end to 'virtual merger'.

Modern healthcare·2001
Same author

Okla. hospital settles dumping charges.

Modern healthcare·2001
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

New prognostic factors and surgical techniques are emerging for renal cell carcinoma (RCC). While cytokine therapy remains standard for metastatic RCC, chemotherapy combinations and stem cell transplantation show potential for improved outcomes.

Area of Science:

  • Oncology
  • Urology
  • Nephrology

Background:

  • Renal cell carcinoma (RCC) incidence is rising, with more diagnoses at earlier stages.
  • Emerging prognostic factors like K1-67, p53/mdm-2, and vascular endothelial growth factor (VEGF) show promise for RCC.
  • Increased early-stage diagnoses fuel interest in localized treatment options for RCC.

Purpose of the Study:

  • To review current and emerging prognostic factors in renal cell carcinoma (RCC).
  • To evaluate the evolving landscape of surgical interventions for localized RCC.
  • To assess the efficacy of current and novel therapeutic strategies for metastatic RCC.

Main Methods:

  • Review of current literature on renal cell carcinoma (RCC) prognostic factors.
  • Analysis of trends in surgical management, including nephron-sparing surgery and laparoscopic nephrectomy.

Related Experiment Videos

  • Evaluation of standard and investigational treatments for metastatic RCC, including cytokine therapy, chemotherapy, and stem cell transplantation.

    • Main Results:

    • Several prognostic factors (K1-67, p53/mdm-2, VEGF) show potential for RCC.
    • Nephron-sparing surgery and laparoscopic nephrectomy are gaining traction as potential standards of care for select RCC patients.
    • Standard cytokine therapy for metastatic RCC has limited benefit; adding chemotherapy or exploring nonmyeloablative stem cell transplantation shows promise.

    Conclusions:

    • Prognostic markers and minimally invasive surgical techniques are advancing RCC treatment.
    • Current metastatic RCC treatments, primarily cytokine-based, offer limited efficacy.
    • Combinations of chemotherapy with immunotherapy and stem cell transplantation represent promising future directions for metastatic RCC management.